Citizens Financial Group Inc. RI Makes New $288,000 Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Citizens Financial Group Inc. RI bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the third quarter, HoldingsChannel reports. The fund bought 1,981 shares of the financial services provider’s stock, valued at approximately $288,000.

A number of other institutional investors have also modified their holdings of the business. Darwin Wealth Management LLC acquired a new position in iShares Biotechnology ETF in the 3rd quarter valued at about $29,000. Highline Wealth Partners LLC acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $30,000. Bbjs Financial Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the second quarter valued at approximately $31,000. Ashton Thomas Securities LLC acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $36,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the third quarter worth $59,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

Shares of IBB opened at $137.96 on Friday. The company’s fifty day moving average is $143.43 and its two-hundred day moving average is $141.81. iShares Biotechnology ETF has a 1 year low of $117.28 and a 1 year high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were issued a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.